Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...

Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Neurocrine (NBIX) initiated a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator, an investigational ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...